2026-04406: SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Consideration of Approval of Transfer of License and Conforming Amendment
Public comment closed .
Get alerted when the next rule lands
New rules open for comment on their own schedule. Pick how you want to hear about them — we email you when one appears.
Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.
Create a free account & build one →Summary
The U.S. Nuclear Regulatory Commission (NRC, the Commission) received and is considering approval of an application filed by Illuminated Holdings, Inc. and its wholly owned subsidiary, SHINE Technologies, LLC, on February 4, 2026. The application seeks NRC approval of the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility, currently held by SHINE Technologies, LLC (the current licensee) to a newly formed company, SHINE Chrysalis, LLC, and issuance of a conforming license amendment. The application also seeks NRC approval of the indirect transfer of control of the construction permit as a result of the establishment of a new intermediate parent company, SHINE Chrysalis Holdings, LLC, which will be the direct corporate parent of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a direct subsidiary of Illuminated Holdings, Inc. The application contains sensitive unclassified non-safeguards information (SUNSI).
The agency’s own summary, as published.
Don't miss the comment window
One Click Politics alerts you on every deadline, hearing, and rule change.
See all rules with comments due soon →